The inferior vena cava (IVC) is the largest vein in the body, which carries de-oxygenated blood to the heart’s right atrium and then to the lungs. Inferior vena cava is the main vessel that returns blood from the lower half of the body to the heart. An IVC filter is a cone-shaped small device, which is implanted in the inferior vena to capture blood clots and to prevent them from reaching to the lungs. These devices are implanted either permanently or temporarily based on patients to patients. IVC filters are placed in the patient when anticoagulant therapy cannot be effective at the risk of pulmonary embolism.
The global market for IVC filters is driven by growing incidences of cardiovascular diseases. According to World Health Organization (WHO), in 2008, around 17.3 million people died from cardiovascular disease (CVD), which is expected to reach 23.3 million by 2030. Few of the factors responsible for the market growth includes increasing number of patients diagnosed with cardiovascular diseases (CVD) across the globe, growing government initiative to increase the awareness about CVD and the devices used for treatment. For instance, in May 2014, a post market surveillance by U.S. Food and Drug Administration (US FDA) provided the information about the implementation of IVC filters coupled with the risk of pulmonary embolism.
In addition, frequent product innovation and product launch by key companies would further boost the market growth of inferior vena cava filters. For instance, in January 2014, Argon Medical Devices, Inc. received U.S.FDA clearance for its Option ELITE retrievable inferior vena cava (IVC) filter. Despite several advantaged offered by IVC filter, the high cost of the product might hamper the market growth to some extent. Similarly, complex regulatory approval of cardiovascular devices might lead to the slow market growth.
Based on product type, the market is segmented into retrievable inferior vena cava filters and permanent inferior vena cava filters. Based on material, the inferior vena cava filters market is segmented into non-ferromagnetic materials and ferromagnetic material. IVC filters made from ferromagnetic materials are also classified as MR conditional.
Based on end user, the global Inferior vena cava filters market has been segmented into hospitals, ambulatory surgical centers and emergency care centers. Hospitals are expected to contribute highest share in the global Inferior vena cava filters market over the forecast period due to increased use of inferior vena cava filter for cardiac surgeries performed each year.
On the basis of regional presence, global Inferior vena cava filters market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to lead the global market due to large demand for the device for cardiovascular disease patients, large geriatric population prone to heart disease. Europe is expected to hold second largest market share in the global IVC filters market. Market in APAC region is expected to witness significant growth rate over the forecast period owing to large patient population and increasing awareness regarding the cardiovascular disease and its treatment options.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/15622
Some of the players operating in global Inferior vena cava filters market Cook Medicals, C. R. Bard, Inc., B. Braun Melsungen AG, Boston Scientific Corporation, Cordis Corporation, Argon Medical Devices, Inc., ALN, are and others.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/15622